Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

In both the high-risk score and low-risk score groups, notable disparities in immune cell infiltration were observed across 21 different types of ... Third, the functional analyses rely on in silico ...

1Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Results: Our single-cell analysis identified and characterized 15 distinct cell populations ... Additionally, our in vivo experiments confirmed that knockdown of ERRFI1, a key gene within the STING ...

The signature included the canonical Wnt target gene BAMBI, which promoted experimental metastasis in mice. Here, we identified three new direct Wnt target genes from the signature, and studied their ...

Over the past decade, several dozen cell and gene therapies have reached market in the U.S., bringing with them the promise of long-lasting benefits for serious diseases. Peter Marks’ fingerprints are ...

(NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult ...

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to ...

An­oth­er CD­MO has been hit by the slow­down of cell and gene ther­a­py R&D.